Health Care · Pharmaceutical Preparations · Nasdaq · CIK 818033 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $0.49Day +1.56%Mkt cap $93M1Y −73.3%Off 52W high −74.0%Vol (1Y) 83.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,293 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest22.5% of sh out |
| Days to cover13.3d |
| 13F net flow (QoQ)+1.30% |
| Top-10 13F concentration67.0% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$150.7M |
| Earnings (TTM)-$30.9M |
| Net margin−13.0% |
| Sales growth 3Y12.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−62.0% |
| 1Y−73.3% |
| 3Y−70.3% |
| 5Y−96.0% |
| 10Y−97.0% |
| Since incept. (ann.)−23.2% |
Total return through 2026-07-29 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)83.3% |
| Ann. volatility (3Y)94.9% |
| Sharpe (1Y)−1.12 |
| Sharpe (3Y)0.07 |
| Max drawdown (1Y)−79.6% |
| Max drawdown (3Y)−90.2% |
| Beta (3Y vs SPY)3.45 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Rubric Capital Management LP | 30.0M | $24M | 15.87% | +0.0% |
| Clearline Capital LP | 12.2M | $10M | 6.46% | +0.0% |
| BlackRock, Inc. | 10.1M | $8M | 5.34% | −1.1% |
| ORBIMED ADVISORS LLC | 9.8M | $8M | 5.19% | new |
| Velan Capital Investment Management LP | 8.8M | $7M | 4.62% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.8M | $6M | 4.13% | new |
| MILLENNIUM MANAGEMENT LLC | 7.6M | $6M | 4.03% | +6.4% |
| Tejara Capital Ltd | 6.3M | $5M | 3.35% | +23.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.04 | −500.0% | $34.7M | −10.8% |
| 2025-12-31 | 2026-02-26 | — | — | $40.6M | −0.5% |
| 2025-09-30 | 2025-11-04 | −$0.10 | — | $38.2M | +16.5% |
| 2025-06-30 | 2025-08-08 | −$0.02 | — | $37.2M | +3.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
CINVANTI 62% · ZYNRELEF 25% · Aponvie 7% · SUSTOL 5%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
